Cilento, M.A.Klein, O.Egan, E.Roberts‐Thomson, R.2025-07-212025-07-212022Australasian Journal of Dermatology, 2022; 63(3):e222-e2250004-83801440-0960https://hdl.handle.net/2440/146192Merkel cell carcinoma (MCC) is a rare and aggressive cutaneous tumour of neuroendocrine cell origin, which can grow rapidly and metastasise early. Localised disease is treated with surgery and radiotherapy. Disease that reaches a more advanced stage can be treated with a variety of different treatment modalities including surgery, radiotherapy, chemotherapy, radionuclide therapy, immunotherapy, and intralesional therapy. We report a case of a patient who had exhausted all local and systemic treatment options and who subsequently had an exceptional response to intralesional injection of Talimogene laherparepvec (TVEC).en© 2022 The Authors. Australasian Journal of Dermatology published by John Wiley & Sons Australia, Ltd on behalf of Australasian College of Dermatologists. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.cancer intervention; chemotherapy<oncology; dermatology; immunology; skin cancer<oncologyHumansHerpesvirus 1, HumanCarcinoma, Merkel CellMelanomaSkin NeoplasmsBiological ProductsTreatment OutcomeOncolytic VirotherapyTalimogene laherparepvec resulting in near‐complete response in a patient with treatment‐refractory Merkel cell carcinomaJournal article10.1111/ajd.138812024-11-13614346Cilento, M.A. [0000-0003-2216-5650]